Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Interleukin33 organize local immune reactions, especially at epithelial barriers.
ST2 is the IL33 receptor. The sST2 rate is higher for patient living with HIV and is an independent predictable factor of mortality. Interleukin33 induce tissue Treg ST2+ lymphocytes proliferation and amphireguline production. Amphireguline is member of epithelial growth factors family, which contributes to tissue repair, and fibrose. Amphireguline also helps immunosuppressives functions. Targetting amphiregulin for people living with HIV who has poor restauration of LTCD4+ could be a future therapy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HIV+ |
| ||
| HIV- STI+ |
| ||
| HIV- STI- |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| biopsie | Procedure | Additional colorectal mucosal biopsies during rectoscopy or colonoscopy |
|
| Measure | Description | Time Frame |
|---|---|---|
| Quantification of amphiregulin plasma levels | Quantification of amphiregulin plasma levels in HIV-infected subjects and correlation these levels with blood TCD4 cell count and clinical parameters (cardiac diastolic dysfunction, organ dysfunctions likely to be secondary to fibrosis phenomena) recorded in the CARDAMONE cohort. | through study completion, an average of 1 year |
| Phenotypic characterization of gut Treg cells and CD8+ T lymphocytes (CTL) isolated from the intestinal mucosa | through study completion, an average of 1 year | |
| Study of fibrosis markers in the intestinal mucosa | through study completion, an average of 1 year | |
| In vitro functional analysis of amphiregulin from isolated CTL of the lamina propria | through study completion, an average of 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Characterization of HIV reservoir of the digestive mucosa | (i) Analysis at the blood and digestive compartment (rectum) for different CD4 CD32a T lymphocyte populations, marker of the viral reservoir; (ii) Quantification HIV DNA and the HIV reservoir competent for replication from blood and gut | through study completion, an average of 1 year |
Not provided
Inclusion Criteria:
Group 1: HIV-infected subjects
NB : an additional inclusion criteria for the Group 1 will be defined after the "phase 0" which will define two levels of fibrosis (low / high)
Group 2: controls not infected with HIV needing a rectoscopy for an STI screening
Group 3: controls not infected with HIV needing a colonoscopy
For the 3 groups:
Inclusion criteria
Exclusion Criteria for the 3 groups
Not provided
Not provided
Not provided
people living with HIV compare to people who are not living with HIV :
- people with high burden of STI / people without burden of STI
Not provided
Not provided
Not provided
Not provided
| blood drawn | Biological | Additional blood drawn by venepuncture |
|
| Determination of antiretroviral drugs levels in digestive tissue and in plasma and correlation between antiretroviral drugs levels and viral reservoir and lymphocyte phenotype | through study completion, an average of 1 year |